• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    GSK (LSE:GSK) Could Be 12% Undervalued Following Fresh Oncology Data

    Simply Wall St·10/27/2026 16:14:45
    Listen to the news

    GSK (LSE:GSK) is back in focus after fresh oncology data, with Jemperli and early stage antibody drug conjugates delivering new trial readouts that sharpen the story around the group’s cancer pipeline.

    The recent oncology headlines arrive as GSK’s shares trade at £19.15, with a 7 day share price return of 3.23% and a 30 day share price return of 3.46%. These partially offset a 90 day share price decline of 5.62% and sit alongside a 1 year total shareholder return of 20.92%, indicating that momentum has picked up again after a softer spell. The longer term total shareholder returns over 3 and 5 years, at 48.34% and 50.50%, show how the story has been building over time rather than in a single burst.

    Spot fresh oncology momentum at GSK, then scan a curated field of peers using our 8 healthcare AI stocks for more ideas in cutting edge cancer and healthcare treatments.

    Fresh oncology wins, hepatitis B approval and a £76.7b market value now collide in one question: Does GSK’s current price still leave enough upside to compensate for the risks investors are taking on the pipeline and patent front?

    Most Popular Narrative: 12% Undervalued

    GSK’s most followed valuation storyline pegs fair value at £21.73, above the current £19.15 share price. This puts real weight on the pipeline delivering as planned under a 7.6% discount rate.

    The main thing that has to go right is that GSK converts its enlarged late stage pipeline, particularly in oncology and long acting HIV and liver disease programs, into commercially meaningful products while delivering the planned £1.9b annual cost savings by 2029.

    The current valuation implies investors are not fully crediting GSK for its stated >£40b 2031 sales outlook and the potential upside from oncology and long acting injectables. This is why this narrative describes the stock as undervalued and bullish.

    See why 217 investors see GSK as 12% undervalued.

    Result: Fair Value of £21.73 (UNDERVALUED)

    Still, the narrative can quickly wobble if loss of exclusivity in key HIV products bites harder than expected or if major late stage oncology trials underdeliver.

    Find out about the key risks to this GSK narrative.

    Next Steps

    Curious whether the mix of oncology promise and patent risk around GSK feels balanced enough for you? Act quickly, review both sides of the story, then weigh the 4 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond GSK?

    If GSK has your attention but you do not want your portfolio leaning on a single story, you may want to broaden your opportunity set with a few targeted stock lists.